Nicole Baranda Balmaceda, MD

GI Oncologist at UT MD Anderson | Conquering Cancer with novel therapies and ctDNA 🧪 in pancreatic cancer | PDAC and CRC research | Millennial dog mom to Nivo

[Nicole Baranda Balmaceda, MD @NBalmacedaMD]

Grateful for @ConquerCancerFd and all my mentors at @CUCancerCenter including @chiaro_del and Dr. Chris Lieu. Through the ASCO YIA, I will study ctDNA and peritoneal tumor DNA to evaluate response to intraperitoneal chemo for pancreatic cancer with peritoneal mets.
@CUHemeOnc

[Arndt Vogel @ArndtVogel]

Safety and efficacy of zoldonrasibplus daraxonrasib in patients with 2L+ KRAS G12D metastatic mPDAC
@ ESMO-Gi
😍>90% DCR in 2nd/3rd line therapy
👉tox driven by daraxonrasib, only 5% treatment discontionuation
👉amazing..
@myESMO @ASCO

[Dr. Cathy Eng @CathyEngMD]

Update of the Japanese #Galaxy trial re: ctDNA following liver resection.
👉🏻non-randomized trial
👉🏻neoadjuvant and/or adjuvant therapy was allowed
👉🏻ctDNA collected 2-10 weeks post op
👉🏻OS was ⬆️for adjuvant chemo if MRD(+)
@OncoAlert @myESMO #ESMO2026
#cancer #cancerresearch

[Nicole Baranda Balmaceda, MD @NBalmacedaMD]

#ASCO26 friendly faces #tumorboardtuesday @MPishvaian @DanielHaldarMD

[David S. Hong MD @DavidHongMD]

Standing ovation for the RASolute302 trial results! @UTMDAnderson @KRASKickers #ASCO26 @RevMedicines

[Nicole Baranda Balmaceda, MD @NBalmacedaMD]

Daraxonrasib is the PDAC IT GIRL! Rowdy crowd at the #ASCO26 plenary session. Applauses heard around the world. An emotional day for many. Congratulations to @RevMedicines and the investigators including @DrShubhamPant @DavidHongMD. And THANK YOU to our patients ❤️ #RASolute302

[Christine Parseghian, MD @ParseghianC]

ctDNA tumor fraction dynamics help identify benefit from EGFRi rechallenge in #mCRC.
📉 Larger TF declines associated w/ response
📈 Higher baseline TF predicted shorter PFS
🩸 ctDNA provided insights beyond CT
Great work @Guv_onc as always for leading this effort! #ASCO26

[Christine Parseghian, MD @ParseghianC]

🙌🏻👏🏻Congratulations to @ScottKopetz on another important advance from BREAKWATER! Seeing E+C improve outcomes when combined with both FOLFOX and now FOLFIRI provides welcome flexibility for treating patients with aggressive BRAF V600E MT #mCRC #CRCsm #ASCO26

[Christine Parseghian, MD @ParseghianC]

🙌🏻👏🏻Congrats to @VanKMorris on another important study in MSS #BRAFV600E #mCRC! Although Nivo added to E+C did not improve survival outcomes, some pts in the initial study experienced years of benefit, highlighting the opportunity for future biomarker discovery. #CRCsm #ASCO26

[Nicole Baranda Balmaceda, MD @NBalmacedaMD]

Very critical research presented by Dr. Soumya Shekhar and @VanMorrisMD. Looking back at patients - is it truly MRD? look out for those “nonspecific/indeterminate” lesions on scans 🔎

[OncLive.com @OncLive]

Important work presented by @VanMorrisMD of @UTMDAnderson at #ASCO26 highlighting the importance of defining and identifying MRD in CRC to guide treatment decisions to eradicate disease and reduce recurrence

@Jonathanwlee23
#CancerCare

[Nicole Baranda Balmaceda, MD @NBalmacedaMD]

I hope you were able to check out Dr. Lee’s @Jonathanwlee23 work on liver transplantation in colorectal cancer with liver metastasis! Thanks for taking great care of people with colon cancer.

[OncLive.com @OncLive]

A key part of #ASCO26 is reconnecting with friends and colleagues. Great hearing about the work @NBalmacedaMD of @UTMDAnderson is doing in #PancreasCancer, especially in the young adult population where incidence is rising.

@Jonathanwlee23
#Oncology
#MedEd

[Nicole Baranda Balmaceda, MD @NBalmacedaMD]

Congratulations to all and to @AWeaverMDPhD on her career development award! You are doing amazing work @CUAnschutz 🎉❤️

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

We're thrilled to officially announce the 2026 class of Conquer Cancer Grants and Awards recipients! 🔬 These grants empower the next generation of physician-scientists to turn innovative ideas into clinical breakthroughs. Congratulations to the new class—see you in Chicago for #ASCO26!

Full list of recipients here: https://t.co/Ltov9bTGYi

#ResearchConquersCancer #ConquerCancer @ASCO

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

We're thrilled to officially announce the 2026 class of Conquer Cancer Grants and Awards recipients! 🔬 These grants empower the next generation of physician-scientists to turn innovative ideas into clinical breakthroughs. Congratulations to the new class—see you in Chicago for #ASCO26!

Full list of recipients here: https://t.co/Ltov9bTGYi

#ResearchConquersCancer #ConquerCancer @ASCO

[NEJM @NEJM]

In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy. Full phase 3 HERIZON-GEA-01 trial results: https://t.co/EoAKVty6RC

[#TumorBoardTuesday @TumorBoardTues]

#TumorBoardTuesday
⌛️1y ago we learned of a major📈in the cure for early stage gastric cancer

📢Join us Tuesday, 05-12-26 at 8PM ET as @SunnieSKim & @aprilchoi_md 🗣️updates to the MATTERHORN trial & Tx for early stage #gastriccancer

RT and bring others into the discussion‼️

[NEJM @NEJM]

Original Article: Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer https://t.co/9y7xLrCuYV

Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer https://t.co/mz3fgnCNUi

#Oncology #Gastroenterology

[Urs Weber MD @UrsWeberMD]

Join us in Chicago! @gotoPER

📅Date: May 31, 2026 | 6:30pm – 8:30pm CDT 
📍Location: Sheraton Grand Chicago Riverwalk | 4th Floor, Chicago 8-10
Program Chair: Enriqueta Felip, MD, PhD
Faculty: Justin Gainor, MD and Urs Weber, MD
📋Link to Registration: https://t.co/mHRsxaU6Zb

[Wungki Park, MD MS @CentralParkWMD]

1/n

Daraxonrasib (RMC-6236), the first-in-human oral 💊RAS(ON) multi-selective tri-complex inhibitor, in previously treated RAS-mutated pancreatic cancer phase I/II study is now published in the New England Journal of Medicine @NEJM

A novel💡 way to shut down ⚔️RAS, one of the most important oncogenic drivers in cancer that had long been considered “undruggable.”

🔗https://t.co/ptfNVcxrb4

Shout out to Brian Wolpin, @CentralParkWMD @GarridoLagunaMD @AlexSpiraMDPhD @salmanpunekar @MeredithPelster @bherzbergmd Nilo Azad Aparna Hegde @DavidHongMD and the whole team who dedicated to this study. @EileenMOReilly

#HBP #HumansBeyondPatients

[U.S. FDA @US_FDA]

The @US_FDA has issued a "safe to proceed" letter allowing the initiation of an expanded access treatment protocol (EAP) for daraxonrasib, an experimental drug targeting pancreatic cancer. Per EAP guidelines, requests must be submitted to the sponsor by U.S.-licensed physicians on behalf of eligible patients. #FDA #PancreaticCancer

https://t.co/ELBngJA3jL

[Oncology Brothers @OncBrothers]

Here is the link to our full discussion w/ @smitha42 on early stage colon and metastatic colo-rectal cancer Treatment Algorithm!

@OncUpdates #OncTwitter #MedX #gism

https://t.co/KkmcuksdlJ

[Dr Amol Akhade @SuyogCancer]

Selected KRAS G12D inhibitors in development .Data from #AACR26